News

Morris Plains, N.J. – – October 01, 2026 -- Solstice Advanced Materials (NASDAQ: SOLS) will release its third-quarter 2026 financial results before market open on November 4, 2026, the specialty materials company confirmed.

Solstice schedules investor call for 8:30 a.m. ET on November 4

Management will host a conference call at 8:30 a.m. Eastern Time the same day to walk analysts and shareholders through the quarterly performance. The session will be webcast live via the Investor Relations section of investor.solstice.com, with accompanying presentation materials posted alongside the broadcast.

Dial-in access offered for North American and international participants

Investors can join the teleconference toll-free at 877-407-8029 from North America, or dial +1 201-689-8029 internationally. A replay of the webcast will be posted shortly after the call ends and will remain accessible for 30 days.

Vancouver – October 01, 2026 -- Graphite One Inc. (TSXV: GPH) (OTCQX: GPHOF) has created a new advanced systems division targeting graphite applications in defense, space and national security markets, while disclosing roughly US$1.58 million in new investor-relations marketing contracts.

Graphite One creates new division to push graphite into defense and space applications

The division will serve as the Company's platform for developing next-generation graphite and graphene technologies beyond battery and energy storage systems. CEO Anthony Huston said the move reflects the recognition that "graphite and graphene are transformational materials in evolving technologies relevant to the energy/defense/national security and space sectors."

New York – October 01, 2026 -- Sharon AI Holdings Inc. (NASDAQ: SHAZ) has closed its inaugural US$356 million committed senior secured, GPU-backed SPV debt facility, priced at a fixed rate of 9.95% excluding fees.

Facility backs GPU deployment for customer contracts

The debt is secured against the Company's GPUs and associated cash flows, funding the deployment of compute infrastructure dedicated to signed customer contracts. The facility supports Sharon AI's plan to build out more than 68,000 NVIDIA GPUs by mid-2027 and is the first in an expected series of GPU financings.

Goldman Sachs and private credit funds join syndicate

The facility drew marquee Australian, Asian and global investors, including Goldman Sachs and select large private credit funds. Jarden Australia acted as sole financial advisor and arranger on the transaction.

Boston – October 01, 2026 -- HoneyNaps, an AI-based sleep health technology company, has completed registration as a clinical research organization (CRO) with South Korea's National Enterprise for Clinical Trials (KoNECT), broadening its role in pharmaceutical and medical device trials worldwide.

HoneyNaps secures CRO registration with KoNECT, expanding multicenter trial capacity

The company has supported clinical trials involving more than 10,000 participants and can now operate multicenter, multidisciplinary studies under its new CRO status. The registration formalizes HoneyNaps' position as a provider of standardized sleep data analysis for pharmaceutical companies, medical device developers, and research organizations.

Dublin – October 01, 2026 -- Neuromod Devices has appointed Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development, moves aimed at accelerating global commercial expansion of its tinnitus treatment device, Lenire.

San Jose, Calif. – October 01, 2026 -- AppZen has launched ZenLM Plus, a family of finance-specialized large language models that outperformed seven frontier AI models on expense audit accuracy while cutting inference costs, the company announced.

Houston and Düsseldorf – October 01, 2026 -- Uniper has reserved future production capacity from Syzygy Plasmonics' NovaSAFTM biogas-to-sustainable aviation fuel platform, joining a growing list of fuel buyers backing the technology ahead of a final investment decision on the company's first commercial plant in Uruguay.

Uniper locks in dual-certified SAF supply to meet EU mandate volumes

The agreement secures capacity under Syzygy's dual-certified pathway, which qualifies for both bio-based and RFNBO (renewable fuels of non-biological origin) SAF categories under European Union mandates. The deal adds commercial weight to Syzygy's planned NovaSAF facilities across Central and South America, with NovaSAF-1 in Uruguay now approaching final investment decision.

Tel Aviv, Israel – October 01, 2026 -- Lutris Pharma reported that its topical B-Raf inhibitor LUT014 achieved Treatment Success in 71.8% of patients with EGFR inhibitor-induced acneiform rash, compared with 38.5% on placebo (p=0.003), in updated Phase 2 data presented at the 35th EADV Congress in Vienna.

LUT014 0.1% gel cuts clinician-assessed rash severity and patient symptom burden

Among the composite endpoint's components, 56.4% of patients on LUT014 0.1% achieved at least a one-grade improvement on the CTCAE v5.0 acneiform rash scale versus 15.4% on placebo (p=0.0002). Using the FACT-EGFRI-18 patient-reported symptom score, 53.8% of treated patients reported at least a five-point improvement versus 28.2% on placebo (p=0.021).

Denver – October 01, 2026 -- LandGate has expanded its spatial intelligence platform to track more than 2,100 data center facilities across 10 European markets, adding site-level power, permitting and connectivity data to its existing U.S. coverage.

The expansion follows LandGate's acquisition by Wood Mackenzie in June 2026 and positions the company as a supplier of site-selection intelligence for hyperscale and AI-driven data center developers operating across Europe.

UK leads European coverage with 500+ facilities amid 70 GW of pending connection requests

The United Kingdom dominates LandGate's European dataset with more than 500 tracked facilities concentrated in the London and Slough corridor, where power connection requests now exceed 70 GW. Germany follows with 450+ facilities centered in Frankfurt, where the EnEfG Act will require new builds to hit a PUE of 1.2 or lower from July 2026 and shift to 100% renewable electricity by 2027.

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Six-participant trial records no serious adverse events over five years

The data, presented by Japan's National Center of Neurology and Psychiatry (NCNP) at the 31st annual International Congress of the World Muscle Society in Hiroshima, Japan, covered an open-label extension of an investigator-initiated clinical trial. All six participants received weekly intravenous dosing of brogidirsen (NS-089/NCNP-02), an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP. After five years of administration, no serious or severe adverse events, anaphylaxis, or discontinuations tied to long-term dosing were recorded.